The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Expanding Biological Understanding of Parkinson's Disease, 2022Deep Phenotyping of Parkinson's Disease Relevant Mitochondrial and Autophagic Mechanisms in Human iPSC-derived Neural Cells
Study Rationale: The causes of Parkinson’s disease (PD) are not fully understood. However, impairment in the function of mitochondria, the powerhouses of the cell, and in autophagy, a process whereby...
-
Therapeutic Pipeline Program, 2022Assessing the Effects of USP30 Inhibitors on the Removal of Damaged Mitochondria in Nerve Cells
Study Rationale: Mitochondrial dysfunction is extensively associated with genetic and sporadic forms of Parkinson’s disease (PD). Yet there are currently no clinical trials that specifically aim to...
-
Spring 2022 RFA: Therapeutic Pipeline Program Pre-Clinical, 2022Assessing the Effects of USP30 Inhibitors on the Removal of Damaged Mitochondria in Nerve Cells
Study Rationale: Mitochondrial dysfunction is extensively associated with genetic and sporadic forms of Parkinson’s disease (PD). Yet there are currently no clinical trials that specifically aim to...
-
Summer 2022 RFP: Expanding Biological Understanding of Parkinson's Disease, 2022Assessing Whether Cholesterol or Its Metabolites Increase the Risk of Developing Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) has been associated with a dysregulation of cholesterol metabolism in brain cells and the accumulation of a protein called alpha-synuclein. Our research is...
-
Research Grant, 2022WATCH-PD Remote Digital Health Technology Extension: Planning Period
Study Rationale: In the WATCH-PD study, we evaluated the use of wearable digital devices to monitor symptoms and quality of life in individuals with early, untreated Parkinson’s disease (PD). This...
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Evaluating the Ability of HSG4112, An Anti-obesity Drug Candidate, to Protect Dopamine-producing Neurons Against Mitochondrial Dysfunction
Study Rationale: Mitochondrial dysfunction in dopamine-producing neurons is one of the hallmarks of Parkinson’s disease (PD) pathology. Inside mitochondria is a protein called Paraoxonase 2 (PON2)...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.